Claire Mazumdar, Ph.D., MBA
Chief Executive Officer
Bicara Therapeutics
Business development and corporate strategy at Rheos Medicines, a biopharmaceutical company in Cambridge, Massachusetts, where she supported a major partnership with Roche
Senior Associate at Third Rock Ventures, focused on company formation and supporting business development for portfolio companies
Ph.D. in Cancer Biology from Stanford Medical School and MBA from Stanford University Graduate School of Business; bachelor’s degree in biological engineering from MIT
Liviu Niculescu, M.D.
Chief Medical Officer
Bicara Therapeutics
Previously Head of Clinical Development for Oncology at bluebird bio
Nine years at Pfizer Pharmaceuticals as Senior Medical Director and nearly seven years as Vice President of Global Medical Affairs at Takeda Oncology
M.D. from the Carol Davila University of Medicine and Pharmacy; master’s degree in Public Health from Harvard University
Glenn J. Hanna, M.D.
Principal investigator from Dana-Farber Cancer Institute
Bicara Therapeutics
Fellowship: Dana-Farber/Partners CancerCare, Hematology/Oncology
Residency: Beth Israel Deaconess Medical Center, Internal Medicine
M.D. from Georgetown University School of Medicine; graduated summa cum laude, a member of Alpha Omega Alpha Honor Society and the Kober Medalist for academic excellence